You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 長江生命科技午後飆升逾80% 附屬疫苗取得進展
格隆匯 11-06 13:55
格隆匯11月6日丨長江生命科技(0775.HK)午後開盤直線飆升,現報0.67港元,漲幅88.73%,暫成交3151.1萬港元,最新總市值64.4億港元。公司午間公告稱,全資附屬公司Polynoma將展示研究性黑色素瘤候選疫苗seviprotimut-L第三階段臨牀研究數據。數據顯示seviprotimut-L對患者的效果改善,無復發存活期較長,不良反應事件發生率低seviprotimut-L具備良好耐受性,治療期間出現的不良反應事件與服用安慰劑的患者類近。認為黑色素瘤抗原疫苗免疫療法研究的初始數據令人鼓舞,有潛力作為侷限性黑色素瘤患者輔助性療法的重要新選項。從黑色素瘤抗原疫苗免疫療法研究中獲得的初步數據亦顯示,seviprotimut-L可能是黑色素瘤疫苗療法的一項重要革新,迄今為止尚未有任何疫苗獲批准用於黑色素瘤輔助性療法。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account